Glitazones and the cardiovascular system.

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · see citing works

An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)

Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,626 · see citing works

15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ

FORMAN, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858 · see citing works

The immune response in atherosclerosis: a double-edged sword

Hansson, G. K., & Libby, P. (2006) · Nature reviews. Immunology · doi:10.1038/nri1882 · Cited by 2,176 · see citing works

Peroxisome Proliferator-Activated Receptor-γ Coactivator 1α (PGC-1α): Transcriptional Coactivator and Metabolic Regulator

Puigserver, P., & Spiegelman, B. M. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0012 · Cited by 2,076 · see citing works

9-cis retinoic acid is a high affinity ligand for the retinoid X receptor

Heyman, R. A., Mangelsdorf, D. J., Dyck, J. A., Stein, R. B., Eichele, G., Evans, R. M., & Thaller, C. (1992) · Cell · doi:10.1016/0092-8674(92)90479-v · Cited by 1,780 · see citing works

Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors

Dreyer, C., Krey, G. D., Keller, H., Givel, F., Helftenbein, G., & Wahli, W. (1992) · Cell · doi:10.1016/0092-8674(92)90031-7 · Cited by 1,373 · see citing works

Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese, and Diabetic Subjects

Graham, T. E., Yang, Q., Blüher, M., Hammarstedt, A., Ciaraldi, T. P., Henry, R. R., Wason, C. J., Oberbach, A., Jansson, P.-A., Smith, U., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054862 · Cited by 1,319 · see citing works

A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ

Pascual, G., Fong, A. L., Ogawa, S., Gamliel, A., Li, A. C., Perissi, V., Rose, D. W., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2005) · Nature · doi:10.1038/nature03988 · Cited by 1,251 · see citing works

Nuclear Receptor Expression Links the Circadian Clock to Metabolism

Yang, X., Downes, M., Yu, R. T., Bookout, A. L., He, W., Straume, M., Mangelsdorf, D. J., & Evans, R. M. (2006) · Cell · doi:10.1016/j.cell.2006.06.050 · Cited by 934 · see citing works

Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis

Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761 · see citing works

Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2

Furuhashi, M., Tuncman, G., Görgün, C. Z., Makowski, L., Atsumi, G., Vaillancourt, E., Kono, K., Babaev, V. R., Fazio, S., Linton, M. F., et al. (2007) · Nature · doi:10.1038/nature05844 · Cited by 724 · see citing works

Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrPC, in Cultured Cells

Shyng, S., Lehmann, S., Moulder, K. L., & Harris, D. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.50.30221 · Cited by 704 · see citing works

Lack of macrophage fatty-acid–binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis

Makowski, L., Boord, J. B., Maeda, K., Babaev, V. R., Uysal, K. T., Morgan, M. A., Parker, R. A., Suttles, J., Fazio, S., Hotamışlıgil, G. S., et al. (2001) · Nature Medicine · doi:10.1038/89076 · Cited by 687 · see citing works

Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors

Schug, T. T., Berry, D. C., Shaw, N. S., Travis, S. N., & Noy, N. (2007) · Cell · doi:10.1016/j.cell.2007.02.050 · Cited by 680 · see citing works

Parallel SUMOylation-Dependent Pathways Mediate Gene- and Signal-Specific Transrepression by LXRs and PPARγ

Ghisletti, S., Huang, W., Ogawa, S., Pascual, G., Lin, M.-E., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.11.022 · Cited by 561 · see citing works

Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription

Tan, N.-S., Shaw, N. S., Vinckenbosch, N., Liu, P., Yasmin, R., Desvergne, B., Wahli, W., & Noy, N. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.14.5114-5127.2002 · Cited by 499 · see citing works

Regulation of CLOCK and MOP4 by Nuclear Hormone Receptors in the Vasculature

McNamara, P., Seo, S., Rudic, R. D., Sehgal, A., Chakravarti, D., & FitzGerald, G. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00401-9 · Cited by 441 · see citing works

Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR7 and RXRa

Tontonoz, P., Graves, R. A., Budavari, A. I., Erdjument‐Bromage, H., Lui, M., Hu, E., Tempst, P., & Spiegelman, B. M. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.25.5628 · Cited by 383 · see citing works

Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-γ coactivator 1α

Arany, Z., Novikov, M., Chin, S., Ma, Y., Rosenzweig, A., & Spiegelman, B. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603615103 · Cited by 374 · see citing works

Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe

Colca, J. R., McDonald, W. G., Waldon, D. J., Leone, J. W., Lull, J. M., Bannow, C. A., Lund, E. T., & Mathews, W. R. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00424.2003 · Cited by 339 · see citing works

Peroxisome Proliferator–Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets

Brown, J. D., & Plutzky, J. (2007) · Circulation · doi:10.1161/circulationaha.104.475673 · Cited by 338 · see citing works

MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity

Wiley, S. E., Murphy, A. N., Ross, S. A., van der Geer, P., & Dixon, J. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701078104 · Cited by 326 · see citing works

MitoNEET is a uniquely folded 2Fe-2S outer mitochondrial membrane protein stabilized by pioglitazone

Paddock, M. L., Wiley, S. E., Axelrod, H. L., Cohen, A. E., Roy, M., Abresch, E. C., Capraro, D. T., Murphy, A. N., Nechushtai, R., Dixon, J. E., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707189104 · Cited by 302 · see citing works

Peroxisome Proliferator–Activated Receptor γ Coactivator-1 (PGC-1) Regulatory Cascade in Cardiac Physiology and Disease

Finck, B. N., & Kelly, D. P. (2007) · Circulation · doi:10.1161/circulationaha.107.670588 · Cited by 281 · see citing works

Insulin-Resistant Heart Exhibits a Mitochondrial Biogenic Response Driven by the Peroxisome Proliferator-Activated Receptor-α/PGC-1α Gene Regulatory Pathway

Duncan, J. G., Fong, J. L., Medeiros, D. M., Finck, B. N., & Kelly, D. P. (2007) · Circulation · doi:10.1161/circulationaha.106.662296 · Cited by 216 · see citing works

A fundamental system of cellular energy homeostasis regulated by PGC-1α

Rohas, L. M., St‐Pierre, J., Uldry, M., Jäger, S., Handschin, C., & Spiegelman, B. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702683104 · Cited by 210 · see citing works

PPARγ regulates adipose triglyceride lipase in adipocytes in vitro and in vivo

Kershaw, E. E., Schupp, M., Guan, H.-P., Gardner, N. P., Lazar, M. A., & Flier, J. S. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00122.2007 · Cited by 209 · see citing works

The Outer Mitochondrial Membrane Protein mitoNEET Contains a Novel Redox-active 2Fe-2S Cluster

Wiley, S. E., Paddock, M. L., Abresch, E. C., Gross, L. A., van der Geer, P., Nechushtai, R., Murphy, A. N., Jennings, P. A., & Dixon, J. E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.c700107200 · Cited by 179 · see citing works

The Peroxisome Proliferator–Activated Receptor-γ Agonist Pioglitazone Increases Number and Function of Endothelial Progenitor Cells in Patients With Coronary Artery Disease and Normal Glucose Tolerance

Werner, C. M., Kamani, C. H., Gensch, C., Böhm, M., & Laufs, U. (2007) · Diabetes · doi:10.2337/db07-0069 · Cited by 160 · see citing works

Cardiac peroxisome proliferator-activated receptor γ is essential in protecting cardiomyocytes from oxidative damage

DING, G., FU, M., QIN, Q., Lewis, W., Kim, H. W., Fukai, T., Bacanamwo, M., CHEN, Y., Schneider, M. D., & Mangelsdorf, D. J. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.06.027 · Cited by 158 · see citing works

Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients

Cabré, A., Lázaro, I., Girona, J., Manzanares, J. M., Marimón, F., Plana, N., Heras, M., & Masana, L. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.04.045 · Cited by 149 · see citing works

Asymmetric Cleavage of β-Carotene Yields a Transcriptional Repressor of Retinoid X Receptor and Peroxisome Proliferator-Activated Receptor Responses

Ziouzenkova, O., Orasanu, G., Sukhova, G. K., Lau, E., Berger, J. P., Tang, G., Krinsky, N. I., Dolnikowski, G. G., & Plutzky, J. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0225 · Cited by 132 · see citing works

Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor–α and Peroxisome Proliferator-Activated Receptor–γ Agonists

Libby, P., & Plutzky, J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.004 · Cited by 127 · see citing works

Hepatic Proprotein Convertases Modulate HDL Metabolism

Jin, W., Wang, X., Millar, J. S., Quertermous, T., Rothblat, G. H., Glick, J. M., & Rader, D. J. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.07.009 · Cited by 126 · see citing works

PPAR? in endothelial cells influences high fat diet-induced hypertension

Nicol, C. J. B., ADACHI, M., AKIYAMA, T., & Gonzalez, F. J. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.10.032 · Cited by 105 · see citing works

High-Density Lipoprotein Hydrolysis by Endothelial Lipase Activates PPARα

Ahmed, W., Orasanu, G., Nehra, V., Asatryan, L., Rader, D. J., Ziouzenkova, O., & Plutzky, J. (2006) · Circulation Research · doi:10.1161/01.res.0000205846.46812.be · Cited by 84 · see citing works

The Differential Interactions of Peroxisome Proliferator-Activated Receptor γ Ligands with Tyr473 Is a Physical Basis for Their Unique Biological Activities

Einstein, M., Akiyama, T. E., Castriota, G. A., et al. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.041202 · Cited by 75 · see citing works

Localization of a pioglitazone response element in the adipocyte fatty acid-binding protein gene.

Harris, P. K. W., & Kletzien, R. F. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10015-1 · Cited by 75 · see citing works

Ligand-activated PPARβ efficiently represses the induction of LXR-dependent promoter activity through competition with RXR

Matsusue, K., Miyoshi, A., Yamano, S., & Gonzalez, F. J. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.05.005 · Cited by 60 · see citing works

Pioglitazone Increases Macrophage Apoptosis and Plaque Necrosis in Advanced Atherosclerotic Lesions of Nondiabetic Low-Density Lipoprotein Receptor–Null Mice

Thorp, E. B., Kuriakose, G., Shah, Y. M., Gonzalez, F. J., & Tabas, I. A. (2007) · Circulation · doi:10.1161/circulationaha.107.698852 · Cited by 59 · see citing works

Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials

Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52 · see citing works

Guiding Ligands to Nuclear Receptors

Michalik, L., & Wahli, W. (2007) · Cell · doi:10.1016/j.cell.2007.05.001 · Cited by 46 · see citing works

Contribution to the standardization of the chromatographic conditions for the lipophilicity assessment of neutral and basic drugs

Giaginis, C., Theocharis, S. E., & Tsantili‐Kakoulidou, A. (2006) · Analytica Chimica Acta · doi:10.1016/j.aca.2006.03.074 · Cited by 44 · see citing works

Pioglitazone shift circadian rhythm of blood pressure from non‐dipper to dipper type in type 2 diabetes mellitus

Anan, F., Masaki, T., Fukunaga, N., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01854.x · Cited by 38 · see citing works

A Widely Used Retinoic Acid Receptor Antagonist Induces Peroxisome Proliferator-Activated Receptor-γ Activity

Schupp, M., Curtin, J. C., Kim, R. J., Billin, A. N., & Lazar, M. A. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.033662 · Cited by 33 · see citing works

Contribution of Targeted Conditional Somatic Mutagenesis to Deciphering Retinoid X Receptor Functions and to Generating Mouse Models of Human Diseases

METZGER, D., & Chambon, P. (2007) · Springer eBooks · doi:10.1007/978-3-540-35109-2_21 · Cited by 14 · see citing works

Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline

Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887 · see citing works

The comparison study of pioglitazone and rosiglitazone on type 2 diabetes with hyperlipemia

Xiang-ji, X. (2009) · Sichuan Medical Journal

Cardiovascular safety of rosiglitazone and pioglitazone

Lu, Y., & Ma, D. (2015) · 药物不良反应杂志 · doi:10.3760/cma.j.issn.1008-5734.2015.02.019

Clinical trials with thiazolidinediones in subjects with Type 2 diabetes – is pioglitazone any different from rosiglitazone?

Doggrell, S. A. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.3.405 · Cited by 29 · see citing works

Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's Disease

Miller, B. W., Willett, K. C., & Desilets, A. R. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q238 · Cited by 128 · see citing works

Pioglitazone vs. Rosiglitazone in Older Patients with Type 2 Diabetes

Mueller, P. S., & FACP., F. (2009) · Journal watch · doi:10.1056/jw200909010000001